Mazdutide (IBI-362, Innovent Biologics) is a once-weekly GLP-1R + GCGR dual agonist with the most advanced Chinese Phase 3 programme in the dual agonist class. The GLORY trial series (GLORY-1 through -3) covers obesity (GLORY-1), T2DM (GLORY-2), and combined metabolic outcomes (GLORY-3). Phase 3 data from GLORY-1 showed 14.6% weight reduction at 24 weeks in Chinese overweight/obese adults — the most comprehensive Chinese-population dataset for a dual GLP-1R/GCGR compound. Alongside survodutide, mazdutide completes the landscape of clinical-stage GLP-1R + GCGR agonists available for comparative mechanistic research.
~14.6%
Weight reduction Phase 3 GLORY-1 (24 weeks)
168 hr
Half-life — once weekly
GLP-1R + GCGR
Dual receptor
GLORY-1/2/3
Phase 3 trial programme
≥99%
Purity — HPLC verified
Mazdutide — Specifications
Mazdutide — specifications
Property
Value
CAS Number
2443039-96-9
Molecular Formula
C₁₅₅H₂₄₇N₄₁O₄₉
Molecular Weight
3601.9 g/mol
Half-life
~168 hr (7 days)
Class
GLP-1R + GCGR dual agonist
Purity
≥99% HPLC verified
COA
Janoshik independent third-party
⚙️
Mechanism of Action — Mazdutide
Mazdutide activates GLP-1R and GCGR with balanced agonism — similar to survodutide in dual receptor mechanism. The key research distinction is its Chinese-population PK/PD data and distinct peptide scaffold, which may show different receptor binding kinetics and tissue distribution than the Boehringer Ingelheim compound.
Mazdutide vs Survodutide — same class, different populations
Both are GLP-1R + GCGR dual agonists with once-weekly dosing. Survodutide’s Phase 2 data comes primarily from Western populations; mazdutide’s Phase 3 GLORY data is from Chinese patients. BMI, body fat distribution, and GLP-1R agonist response differ systematically across Asian vs Western populations — mazdutide’s dataset provides the reference for this population. For researchers comparing dual agonist response across ethnic groups, having both compounds available enables parallel-arm designs.
Key Research Studies & Clinical Data
GLORY Phase 3 programme — mazdutide
Trial
Population
Duration
Weight result
GLORY-1 Phase 3
Chinese obese/overweight adults (BMI ≥28), n=248
24 weeks
14.6% vs 3.3% placebo (4mg dose)
GLORY-2 Phase 3
Chinese T2DM patients inadequately controlled on metformin
Mazdutide vs survodutide vs retatrutide in DIO mouse — same dose nmol/kg × 8 weeks. Standardised endpoint panel: weight, fat, glucose, liver fat. Enables direct potency/selectivity comparison on identical background.
Mazdutide (IBI-362) is a once-weekly GLP-1R + GCGR dual agonist developed by Innovent Biologics. It has the most advanced Phase 3 programme for this class in China — the GLORY series — with data in both obesity and T2DM populations.
How does mazdutide compare to survodutide?
Both are once-weekly GLP-1R + GCGR dual agonists with similar mechanisms. Mazdutide has more Phase 3 data; survodutide has more Western-population data and NASH-specific data. For comparative mechanistic research, running both compounds in parallel allows isolation of scaffold-specific vs mechanism-class effects.
What is the GLORY trial?
GLORY is the Phase 3 clinical trial programme for mazdutide in China, comprising GLORY-1 (obesity), GLORY-2 (T2DM), and GLORY-3 (combined outcomes). GLORY-1 showed 14.6% weight reduction at 24 weeks vs 3.3% placebo.
What formats does QSC supply mazdutide in?
QSC supplies mazdutide as lyophilised research vials, ≥99% purity HPLC verified with Janoshik COA. Ships domestically from QSC warehouses in USA, EU, UK, Canada, and Australia.
Is mazdutide approved outside China?
Mazdutide is in Phase 3 trials in China and has not received FDA or EMA approval. QSC supplies it for laboratory research use only.
Research Use Only: All QSC compounds are sold strictly for laboratory research purposes. Not for human use. Not approved by the FDA or equivalent regulatory bodies for human administration. All purchases confirm research intent and compliance with applicable local regulations.
